SOLANBRIDGE GROUP INC
OOTC:SLNX0.00
USD
+0.00
(-99.00%)
ISIN
US83412T1043
CUSIP
83412T104
Return %
Stock
S&P 500
1Y
0.00
14.20
3Y
0.00
81.12
5Y
-99.00
68.34
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- CEO
- Redgie T. Green
- Full Time Employees
- - -
- Sector
- Health technology
- Industry
- Pharmaceuticals: other
- Address
- PO Box 147199 Edgewater CO United States 80214
- IPO Date
- Jun 29, 2007
- Website
- solanbridgegroup.com
- Similar Companies
- Business
- Solanbridge Group, Inc. (SLNX) operates as a biotechnology company focused on the research, development, and production of nutraceutical and cosmetic products, with emphasis on cannabidiol (CBD) oil and related hemp-derived offerings. The company provides CBD hemp oil produced in states including Colorado, Nevada, and California; CBD-infused personal care products; and engages in the development of additional cannabinoid-based nutraceuticals and cosmetics. It targets the medical marijuana and wellness sectors, serving consumers seeking natural health and beauty solutions through its operations primarily in the United States. Founded in 2000 and headquartered in Spring, Texas, with references to locations in The Woodlands, Texas; Lakewood, Colorado; and Edgewater, Colorado, Solanbridge Group maintains a minimal operational footprint as a penny stock entity trading on OTC markets. The company, originally incorporated in Nevada and re-domiciled to Maryland in 2013, has historically pursued diversified holdings including subsidiaries like David's Steak and Seafood Restaurant and Advanced Medical Sales LLC, though current emphasis rests on biotechnology ventures. In recent developments, Solanbridge Group acquired a 51% stake in BICOM, LLC, marking a strategic expansion into associated business interests as of 2024. The company reports ongoing product development in CBD oil without notable funding rounds, partnerships, or new launches disclosed in the past 1-2 years, while maintaining its focus amid a low market capitalization of approximately $4,760.